US Government Can Take Share of Canadian Drug Sales Under Pricing Deals

Newly disclosed government agreements reveal that the U.S. government is poised to take a share of revenue from pharmaceutical sales in Canada and other countries. According to documents obtained by consumer-advocacy group Public Citizen Inc., bilateral pricing deals struck with major drug makers like Pfizer Inc. and Eli Lilly & Co. establish mechanisms to repatriate foreign revenues back to American taxpayers, leveraging massive U.S. drug spending to force international pricing shifts.

How Bilateral Drug Pricing Deals Target International Markets

The U.S. government has pursued a most-favoured-nation drug-pricing policy with more than a dozen major pharmaceutical companies. According to White House documents, the administration demands that prices outside the United States increase to offset lower prices domestically. The newly released files, obtained through a freedom of information request and subsequent lawsuit, show that Canada is one of eight “specified countries” targeted under an agreement signed with Eli Lilly on Feb. 23.

The Lilly agreement defines “specified countries” as Canada, Denmark, France, Germany, Italy, Japan, Switzerland, and the United Kingdom. Doug Clark, a former executive director of Canada’s Patented Medicine Prices Review Board (PMPRB), noted to The Globe that the agreement defines the most-favoured-nation price as the second-lowest international price. He stated that it is unlikely Canada would frequently sit in that position, adding that “the pressure is really on the countries setting the floor.”

Did you know? According to annual reports from Canada’s Patented Medicine Prices Review Board, the average U.S. list price of a drug is more than three times higher than the Canadian price, placing Canada among the developed nations with higher relative pricing structures.

Revenue Sharing and Pfizer’s Agreement Details

While the Pfizer agreement with the Department of Health and Human Services (HHS) redacts the explicit list of targeted nations, it provides deeper structural details regarding financial returns. According to the documents, beginning Jan. 1, Pfizer agreed to share a portion of the net increased revenue realized from ex-U.S. sales of a redacted list of medications with HHS.

When questioned about whether these deals mean the U.S. government will take a direct cut of foreign sales, HHS pointed to a social-media post by White House spokesperson Kush Desai. Replying to a journalist, Desai quoted previous press releases stating that drug companies would “repatriate increased foreign revenue,” though those official releases did not explicitly confirm direct government collection of those funds. Neither Pfizer nor Lilly directly answered inquiries regarding whether they increased Canadian prices to meet these terms.

Canada’s Pharmaceutical Policy Response and Industry Pressures

The pharmaceutical industry in Canada has long pushed for higher prices and accelerated approval timelines from public health insurance plans, which rank among the longest in G7 countries. In response to these intensifying geopolitical pressures, the federal government established a pharmaceutical task force this spring. The task force delivered a report containing 39 recommendations in July, with Ottawa expected to act by the end of the year.

Innovative Medicines Canada, the primary lobby group for patented drug manufacturers, asserts that Canada must alter its policies to remain a reliable market for foreign investment. Meanwhile, Mina Tadrous, a Canada Research Chair in real world evidence and pharmaceutical policy at the University of Toronto, suggests that policymakers and drug companies should pursue creative compromises. He notes that Ottawa and provincial governments could potentially permit higher drug prices in exchange for an expanded domestic manufacturing footprint or increased research and development spending.

Frequently Asked Questions

What is a most-favoured-nation drug-pricing policy?

According to White House documents, it is a policy where the U.S. government pressures major pharmaceutical companies to raise prices outside the United States to offset lower domestic prices.

Which countries are targeted in the Eli Lilly agreement?

According to documents published by Public Citizen Inc., the Eli Lilly agreement defines eight specified countries: Canada, Denmark, France, Germany, Italy, Japan, Switzerland, and the United Kingdom.

How do Canadian drug prices compare to U.S. prices?

According to the Patented Medicine Prices Review Board, the average U.S. list price of a drug is more than three times higher than the Canadian price.

Stay Informed on Global Health Policy

Subscribe to our newsletter for ongoing updates on pharmaceutical pricing, trade agreements, and domestic healthcare impacts.

Subscribe Now

Leave a Comment